- Home
- VCYT vs OGN Comparison
VCYT vs OGN Comparison
Compare VCYT & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCYT
- OGN
- Stock Information
- Founded
- VCYT 2006
- OGN 1923
- Country
- VCYT United States
- OGN United States
- Employees
- VCYT N/A
- OGN N/A
- Industry
- VCYT Medical Specialities
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- VCYT Health Care
- OGN Health Care
- Exchange
- VCYT Nasdaq
- OGN Nasdaq
- Market Cap
- VCYT 2.6B
- OGN 2.7B
- IPO Year
- VCYT 2013
- OGN N/A
- Fundamental
- Price
- VCYT $34.84
- OGN $10.57
- Analyst Decision
- VCYT Buy
- OGN Buy
- Analyst Count
- VCYT 9
- OGN 3
- Target Price
- VCYT $39.89
- OGN $17.33
- AVG Volume (30 Days)
- VCYT 895.7K
- OGN 3.6M
- Earning Date
- VCYT 11-05-2025
- OGN 10-30-2025
- Dividend Yield
- VCYT N/A
- OGN 0.75%
- EPS Growth
- VCYT N/A
- OGN N/A
- EPS
- VCYT 0.34
- OGN 2.69
- Revenue
- VCYT $479,129,000.00
- OGN $6,281,000,000.00
- Revenue This Year
- VCYT $14.48
- OGN N/A
- Revenue Next Year
- VCYT $9.79
- OGN $0.79
- P/E Ratio
- VCYT $102.86
- OGN $3.95
- Revenue Growth
- VCYT 19.91
- OGN N/A
- 52 Week Low
- VCYT $22.61
- OGN $8.01
- 52 Week High
- VCYT $47.32
- OGN $19.05
- Technical
- Relative Strength Index (RSI)
- VCYT 59.94
- OGN 54.85
- Support Level
- VCYT $31.81
- OGN $10.05
- Resistance Level
- VCYT $36.85
- OGN $11.29
- Average True Range (ATR)
- VCYT 1.40
- OGN 0.35
- MACD
- VCYT 0.06
- OGN 0.00
- Stochastic Oscillator
- VCYT 60.91
- OGN 44.76
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.